AffyImmune Therapeutics Revenue and Competitors

Claim your profile

Natick, MA

Location

$28.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AffyImmune Therapeutics's estimated annual revenue is currently $2.8M per year.(i)
  • AffyImmune Therapeutics's estimated revenue per employee is $155,000
  • AffyImmune Therapeutics's total funding is $28.9M.

Employee Data

  • AffyImmune Therapeutics has 18 Employees.(i)
  • AffyImmune Therapeutics grew their employee count by 50% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.

keywords:N/A

$28.9M

Total Funding

18

Number of Employees

$2.8M

Revenue (est)

50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AffyImmune Therapeutics News

2022-04-06 - AffyImmune Therapeutics to Present Poster at American ...

NATICK, Mass., April 6, 2022 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A1958%$63M
#2
$3.1M1912%N/A
#3
N/A2150%$40M
#4
$3M21N/AN/A
#5
$2.3M230%N/A